Literature DB >> 7484866

Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women.

V Guetta1, R M Lush, W D Figg, M A Waclawiw, R O Cannon.   

Abstract

Our study demonstrates that tamoxifen, when administered to postmenopausal women at a conventional dosage, reduces LDL levels and protects LDL from oxidation. The protective effect of tamoxifen against the development of breast cancer in women considered at risk is being investigated in a placebo-controlled trial sponsored by the National Institutes of Health. Whether tamoxifen also protects against the development of cardiovascular disease in this trial is also of considerable interest.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7484866     DOI： 10.1016/s0002-9149(99)80302-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  6 in total

1.  Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF 4227, in healthy postmenopausal women.

Authors:  Maurizio Civelli; Alessandro Piero Monici Preti; Valentina Cenacchi; Ivano Rondelli; Daniele Guastalla; Antoine Tarral; Philippe Dostert; Yann Guillevic; Marie-Claude Homery
Journal:  Br J Clin Pharmacol       Date:  2007-03-16       Impact factor: 4.335

Review 2.  The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer.

Authors:  Lorenzo Rossi; Olivia Pagani
Journal:  Breast Care (Basel)       Date:  2015-09-11       Impact factor: 2.860

Review 3.  Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Authors:  F Khosrow-Khavar; K B Filion; S Al-Qurashi; N Torabi; N Bouganim; S Suissa; L Azoulay
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

4.  Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer.

Authors:  Farzin Khosrow-Khavar; Nathaniel Bouganim; Kristian B Filion; Samy Suissa; Laurent Azoulay
Journal:  Am J Epidemiol       Date:  2020-10-01       Impact factor: 4.897

5.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

Review 6.  Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.

Authors:  J Ribeiro; B Sousa; F Cardoso
Journal:  EJC Suppl       Date:  2013-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.